Click here​ to access the abstract book.

Dear GOC colleagues and partners, 

We are finally back in person! 

It is our great pleasure to invite you to join us at the 40+ Annual General Meeting (AGM 2023), which will take place from June 6, 8-10, 2023 in Ottawa, Ontario. 

As Canada's capital, Ottawa is the perfect place to experience some of the country's best attractions, celebrations, and flavours in one welcoming city. With its unique blend of urban and rural beauty, year-round outdoor activities, and vibrant neighbourhoods, the Ottawa region is best explored over three days or more. Learn more about this beautiful city​ and how you can explore it during your time with us in June. 

We will take you on a learning journey as AGM 2023 is planned to build on the knowledge that will be shared during CPD 2023 on April 27-28, 2023, in Toronto, ON. We will go from theory to action to the future of gynecologic oncology. From attendees to speakers to sponsors, we hope to attract a great number of participants from across Canada, from various disciplines and with the eagerness to share the latest advancements in research and practice in the field of gynecologic oncology. 

As a standing meeting, AGM 2023 is an engaging professional development event that will offer access to local, national, and world-renowned speakers. The AGM Program Planning Committee meticulously designed a captivating program which will feature plenary talks, abstract presentations, a tumor board, debate and so much more. Additionally, select experts will lead various knowledge-sharing opportunities such as the Joint SCC-GOC Colposcopy Workshop outlining the latest on the management of HPV and colposcopy. 

The long-overdue celebration for our 40th anniversary will take place during the gala. The pandemic did not permit us to have a full celebration in 2020; we now can put on our dancing shoes and to also reflect on the great work GOC has done over the past 40+ years with the help of all its members, partners, and sponsors. We will celebrate Dr. Walter Gotlieb as the presidential medal recipient and all those who contributed to the good functioning of the Society in 2020, 2021, and 2022. We will say good-bye to Carine Trazo, our current Managing Director whose efforts in transforming the Society cannot be understated but we also welcome Cidalia Hodnett Sluce, the new National Manager who will continue to build on the foundation that has been established over the past few years. 

We are excited for you, for GOC and for the future of gynecologic oncology in Canada as we strive to improve the care of women with or at risk of gynecologic cancer by raising standards of practice, encouraging ongoing research, promoting innovation in prevention, care, and discovery, and advancing awareness. 

Join us at AGM 2023 in Ottawa, where the future of our discipline awaits us! 

We are looking forward to seeing you in person again! 

Sincerely, 

Alon Altman, MD 

President, GOC 

Tomer Feigenberg, MD 

Chair, AGM Program Planning Committee 

Anne-Marie Bergeron

Quantifying platinum sensitivity as a marker for response to PARP inhibition in patients with advanced ovarian cancer.

Learning objectives:

At the end of this session, participants will:

• Describe the pathology-based Chemotherapy Response Score (CRS) and its relationship with oncological outcomes
• Use the CRS as a potential tool in counseling prior to PARP inhibitor initiation, in addition to germline and homologous recombination deficiency testing 

Conflict of Interest​

Annie Leung

Characterization of a three-dimensional culture system representative of disease progression in ovarian cancer.

Learning objectives:

At the end of this session, participants will: 

• Identify PEO1, PEO4, and PEO6 as pre-clinical model of progression of high grade ovarian cancer
• Describe the morphologic, viability, proliferation, and metabolic activity of PEO1, PEO4, and PEO6 in ultra-low attachment plate 

Conflict of Interest​

Cristina Mitric

Gestational Trophoblastic Neoplasia (GTN): Does Centralization of Care Impact Clinical Management?

Learning objectives:

At the end of this session, participants will: 

• Describe differences between GTN management before and after centralization.
• Identify elements that can be included program that centralizes GTN care.

Conflict of Interest​

David Knigin

PARG (Poly-(ADP-ribose)-glycohydrolase) localizes from the nucleus to the cytoplasm following neoadjuvant chemotherapy in high-grade serous ovarian carcinoma (HGSO)

Learning objectives:

At the end of this session, participants will: 

• Describe the possible applications of PARG protein expression in ovarian cancer

Conflict of Interest​

Elise de Castro Hillmann

Economical impact of ERAS implementation in gynecologic oncology surgery – a five-year study in Canada.

Learning objectives:

At the end of this session, participants will: 

• Describe the economic impact of Enhanced Recovery After Surgery (ERAS) in the high-volume gynecologic oncology (GO) surgery division in a Canadian hospital during five years
• Determine if ERAS implementation in this Canadian gynecologic oncology large volume centre was economically beneficial

Conflict of Interest​

Elisabeth Spenard

Characterization of Epithelial Ovarian Cancer Based on Multi-Gene Tumour Testing and Homologous RecomBinatiOn Deficiency (HRD) Testing (COMBO).

Learning objectives:

At the end of this session, participants will: 

• Understand the correlation of tumour and germline pathogenic variants in advanced epithelial ovarian cancer (EOC) based on multi-gene new-generation sequencing.
• Describe the clinical benefits of tumour-first multi-gene testing as a streamline approach to genetic testing for EOC patients.

Conflict of Interest​

Emma Gerber

Predicting chemoresponsiveness in epithelial ovarian cancer patients using circulating small extracellular vesicle-derived plasma gelsolin.

Learning objectives:

At the end of this session, participants will: 

1. Review current biomarkers of epithelial ovarian cancer and understand their limitations,
2. Describe the clinical application of extracellular vesicle-based biomarkers,
3. Assess the potential of small extracellular vesicle-derived plasma gelsolin as a predictive biomarker platinum resistance in epithelial ovarian cancer.

Conflict of Interest​

Gabriel Levin

Ascites interleukin-10 levels and oncological outcomes in ovarian cancer.

Learning objectives:

At the end of this session, participants will: 

• Determine the association of ascites IL-10 concentration with progression free survival in ovarian cancer.
• Establish the independent factors associated with progression free survival in ovarian cancer.

Canadian gynecologic oncology publications by province.

Learning objectives:

At the end of this session, participants will: 

• Determine the scientific production of the different provinces in gynecologic oncology.
• Describe which factors are associated publication metrics in Canadian gynecologic oncology.

Conflict of Interest​

Hamad Alharbi 

The use of intraperitoneal chemotherapy in patients with stage IV high-grade serous ovarian carcinoma.

Learning objectives:

At the end of this session, participants will: 

• Identify factors affecting survival outcomes in patients with stage IV high grade serous ovarian carcinoma receiving intraperitoneal chemotherapy compared to intravenous chemotherapy.

Conflict of Interest​

Julia Boucher

Enhanced recovery after surgery for gynecologic oncology patients undergoing abdominal hysterectomy during the COVID-19 pandemic.

Learning objectives:

At the end of this session, participants will: 

• Understand the effects of enhanced recovery after surgery (ERAS) on patients undergoing abdominal hysterectomy.
• Analyze the potential for ERAS to address resource limitations and challenges arising from situations such as the COVID-19 pandemic. 
• Collaborate with fellow professionals to incorporate ERAS into their practice, leveraging interdisciplinary teamwork to promote patient-centered care and optimize surgical outcomes. 

Conflict of Interest​

Julie Nguyen

Frailty Assessment for Risk prediction in Gynecologic Oncology (FARGO study): Physician Acceptability Substudy.

Learning objectives:

At the end of this session, participants will: 

• Define frailty and validated measures frailty
• Describe feasibility and acceptability assessments of clinical tools
• Discuss the feasibility and acceptability of the clinical frailty scale and frailty phenotype in a cohort of physicians
• Explore future avenues for research in the measurement of frailty

Conflict of Interest

Laura Hopkins

Development of a Patient Decision Aid for Advanced Ovarian Cancer Patients Who Are Considering Niraparib Maintenance Therapy in the Front-line Setting

Learning objectives:

At the end of this session, participants will: 

• Describe what a Patient Decision Aid (PtDA) is and under what conditions a PtDA may help patients.
• Identify a specific and common example of when a PtDA can be helpful in practice for ovarian cancer patients
• Determine what is involved in creation of a PtDA and when they need to be 

Conflict of Interest​

Mariana Pilon Capella

Survival Outcome in metastatic Ovarian Cancer patients on PARP inhibitors: A Real Life Data.

Learning objectives:

At the end of this session, participants will: 

• Describe the expected progression free survival post PARP inhibitor maintenance treatment for ovarian cancer 
• Identify factors that may affect recurrence in the primary and recurrent settings. 
• Integrate the real-life findings of a single hospital center into future practice when considering PARP inhibitors in the primary or recurrent setting.

Conflict of Interest​

Melissa Lavecchia

Frailty and gynecologic cancer survivorship: A cross-sectional analysis of the Canadian Longitudinal Study on Aging. 

Learning objectives:

At the end of this session, participants will: 

• Describe a common way of operationalizing frailty using the deficit accumulation model.
• Determine the prevalence of frailty among community-dwelling older individuals with a history of gynecologic cancer.
• Identify the implications of frailty among individuals with a history of gynecologic cancer on resource use.

Conflict of Interest​

Niyati Malkani

Enhanced Recovery after Surgery (ERAS) in Gynecologic Oncology: Meaningful Improvements in Patient Outcomes with Implementation of the ERAS Protocol.

Learning objectives:

At the end of this session, participants will: 

• Implementation of an enhanced recovery pathway in Gynecologic Oncology (ERGO) at a tertiary Canadian center.
• Reduce postoperative complications, hospital length of stay, post-op pain and analgesic requirements.
• Provide proof of concept and feasibility of large-scale implementation of enhanced recovery bundle for surgical patients

Conflict of Interest​

Ramlogan Sowamber

Introducing the Ovarian Cancer Observatory: studying the impact of and learning from Opportunistic Salpingectomy (OS).

Learning objectives:

At the end of this session, participants will: 

• Describe opportunistic salpingectomy and recognize its benefits for females of the general public.
• Contrast opportunistic salpingectomy with other forms of surgical interventions, such as bilateral salpingo-oophorectomy
• Assess the efficacy of opportunistic salpingectomy as it relates to decreasing ovarian cancer risk
• Evaluate the molecular and genomic underpinnings of tumours that arise post-opportunistic salpingectomy

Conflict of Interest​

Sabrina Piedimonte

Correlating the KELIM score and the Chemo-Response Score to Predict Chemo-sensitivity in Ovarian Cancer.

Learning objectives:

At the end of this session, participants will:

• Determine the correlation between preoperative KELIM score and pathologic chemosensitivity at interval surgery
• Assess the PFS benefit in patients with favorable KELIM and favorable chemosensitivity
• Discuss whether KELIM score can be used as a preoperative marker of chemosensitivity in ovarian cancer.



Conflict of Interest​

Sarah Mah

Palliative care utilization across health sectors for patients with gynecologic malignancies in Ontario, Canada.

Learning objectives:

At the end of this session, participants will: 

• Describe the patterns of palliative care initiation in patients dying of gynecologic cancers in Ontario, Canada
• Identify palliative care health resource utilization trends by healthcare sector (community vs. institutional, specialist vs. non-specialist)
• Determine predictors of first initiating palliative care during hospital admission
• Understand the concepts of integrated and early vs. late and reactionary palliative care in gynecologic oncology

Conflict of Interest​

Tal Milman

Predictors and outcomes of same day discharge after minimally invasive hysterectomy in gynecologic oncology.

Learning objectives:

At the end of this session, participants will: 

• Describe which factors promote or prevent same day discharge after minimally invasive hysterectomy in gynecologic oncology. 
• Critique how your current practice compares with the findings and the factors described. 
• Identify 2 areas that prevent same day discharge in your current standard disposition plan following minimally invasive gynecologic surgery that may be amenable to change.  

Conflict of Interest​

Yoav Brezinov

Exploring the Impact of COVID-19 Pandemic on Ovarian Cancer Care.

Learning objectives:

At the end of this session, participants will: 

• Study the practice changes in the treatment of ovarian cancer during the COVID-19 pandemic
• Describe the impact of COVID-19 restrictions on ovarian cancer diagnosis
• Compare the overall survival and progression free survival of patients with ovarian cancer during this period 

Conflict of Interest​

Anisha Dubey



Retrospective review on different hysterectomy approaches for endometrial cancer

Learning objectives:

At the end of this session, participants will:

• Review the different hysterectomy approaches used to treat endometrial cancer
• Understand the surgical and oncological outcomes of these approaches
• Determine if surgical approach is an independent risk factor for endometrial cancer recurrence

Conflict of Interest​

Audrey Feng-Emond

ERAS Recovery Protocol's Impact on Vulvar Oncologic Surgical Outcomes.

Learning objectives:

At the end of this session, participants will: 

• Describe vulvar cancer surgical outcomes including complications.
• Analyze ERAS' impact on vulvar cancer surgical outcomes.
• Determine the Centre hospitalier de l'Université de Montréal's (CHUM) compliance to ERAS guidelines for vulvar cancer surgery.

Opioid Prescription Adequacy in Endometrial Cancer Patients Undergoing Hysterectomy Under ERAS Protocol.

Learning objectives:

At the end of this session, participants will: 

• Analyze opioid discharge prescriptions adequacy when compared to opioid consumption 24h pre-discharge in endometrial cancer patients undergoing a hysterectomy.
• Describe the Centre hospitalier de l'Université de Montréal's (CHUM) multimodal analgesia pain management protocol in endometrial cancer patients undergoing a hysterectomy.
• Identify ERAS multimodal analgesia pain management recommendations' role in post-hysterectomy recovery in endometrial cancer patients.

Conflict of Interest​

Brenna Swift

How long do we need to monitor hCG after evacuation of a complete hydatidiform mole?

Learning objectives:

At the end of this session, participants will: 

A multicentre, randomized controlled trial to assess video-based coaching in gynecology and gynecologic oncology.

Learning objectives:

At the end of this session, participants will: 

Conflict of Interest​

David Knigin

The impact of surgical staging on adjuvant therapy decision in patients with grade 1 endometrial cancer on preoperative biopsy

Learning objectives:

At the end of this session, participants will: 

• Describe the possible applications of PARG protein expression in ovarian cancer.

Conflict of Interest​

David Huntsman

Learning objectives:

At the end of this session, participants will: 

Conflict of Interest​

Diane Provencher

Exactis-03: A Phase I trial of the combination of olaparib and navitoclax in women with high grade serous ovarian cancer and triple negative breast cancer.

Learning objectives:

At the end of this session, participants will: 

Conflict of Interest​

Elise de Castro Hillmann

ERAS pathway outcomes in gynecological oncology – 5 years implementation evolution of a 2420 patients' cohort.

Learning objectives:

At the end of this session, participants will: 

Conflict of Interest​

Eva Kadoch

Surgical Approaches and Clinical Outcomes in Ovarian Cancer: Insights from a Retrospective Cohort Study.

Learning objectives:

At the end of this session, participants will: 

• Describe this retrospective cohort study of 240 patients.
• Differentiate between interval debulking surgery (IDS) and primary debulking surgery (PDS) and understand the criteria and factors that influence the selection of IDS or PDS for individual patients.
• Determine the surgical and clinical outcomes of IDS and PDS in patients with ovarian cancer.

Robotic Surgery Outcomes Are Not Affected by Body Mass Index: A Single-Center Study on 1329 Endometrial Cancer Patients. 

Learning objectives:

At the end of this session, participants will: 

• Describe this retrospective cohort study of 1,329 patients.
• Understand the impact of body mass index (BMI) on surgical outcomes in patients with endometrial cancer undergoing robotic surgery.
• Compare patient outcomes, including surgical times, estimated blood loss, recovery room stay, length of hospitalization, and complication rates, across BMI categories.

Conflict of Interest

Florentin Racovitan

Outcome of elderly patients with endometrial cancer.

Learning objectives:

At the end of this session, participants will: 

• Differences in Overall Survival (OS), Disease Free Survival (DFS), and Cancer Specific Survival (CSS) in elderly women (≥ 70 years) compared with younger patients (<70 years) with endometrial cancer (EC). 
• Differences in Treatment patterns in elderly EC patients compared with younger EC patients. 
• Changes in elderly patients' survival (OS, DFS, and CSS) and factors that correlated with these changes

Conflict of Interest​

Gabriel Levin

Elevated expression of the immunosuppressive cytokine IL-10 in ascites of women with ovarian cancer.

Learning objectives:

At the end of this session, participants will: 

•  Determine which ovarian mass characteristics are associated with ascites IL-10.
• Describe the spectrum of ascites IL-10 concentrations in ovarian masses. 

Predictors of high number of citations per year in Canadian gynecologic oncology publications.

Learning objectives:

At the end of this session, participants will: 

•  Identify the predictors of high number of citation per year (CPY) for research publication in Canadian gynecologic oncology.
• Describe the part of each province in the number of citation per year groups.

Top-cited articles per year in Canadian Gynecologic Oncology: A bibliometric analysis.

Learning objectives:

At the end of this session, participants will

•  Identify the subjects and methodology of the most cited per year publications.
• Describe the changes in publications trend following 2016.

Robotic surgery in gynecology – a bibliometric analysis.

Learning objectives:

At the end of this session, participants will:

• Identify the trends in robotic surgery publications across the years.
• Describe the role of country's level of income in robotic surgery literature.

Patterns of recurrences in high-risk endometrial patients staged by sentinel lymph node biopsy with or without completion lymphadenectomy.

Learning objectives:

At the end of this session, participants will:

• Identify pattern of recurrence in high-risk endometrial cancer.
• Describe the role lymph node assessment with pattern of recurrence,

Time interval between endometrial biopsy and surgery for endometrial intraepithelial neoplasia.

Learning objectives:

At the end of this session, participants will: 

• Identify the association of wait time from biopsy to surgery with post operative histology.
• Describe the association of wait time from biopsy to surgery with well known prognostic characteristics of endometrial carcinoma.

Machine learning for prediction of endometrial carcinoma in women with endometrial intraepithelial neoplasia.

Learning objectives:

At the end of this session, participants will:

•  Identify predictive clinico-pathologic factors that can indicate concurrent endometrial carcinoma among patients with endometrial intraepithelial neoplasia.
• Describe the role of machine learning in possible prediction models of post operative endometrial carcinoma in patients with endometrial intraepithelial neoplasia.

Conflict of Interest​

Jacob McGee

Clinical outcomes for patients with advanced and recurrent endometrial cancer receiving first-line therapy in Alberta, Canada. 

Learning objectives:

At the end of this session, participants will: 

• Identify patient characteristics associated with real-world first-line systemic therapy use in advanced or recurrent endometrial cancer in Alberta, Canada
• Describe real-world overall survival for patients with advanced or recurrent endometrial cancer receiving first-line therapy in Alberta, Canada
• Identify patient and treatment characteristics associated with improved overall survival outcomes in these patients

Utilization of social media to disseminate gynecologic oncology and cannabis research to Canadian patients: A GOC Medical Cannabis CoP.

Learning objectives:

At the end of this session, participants will:

Conflict of Interest​

Jade Desilets

Contraception counselling and pregnancy screening practice within an oncologic department; an institution experience.

Learning objectives:

At the end of this session, participants will: 

• Review the available evidence on pregnancy screening and contraception counselling practice in the context of oncological treatment 
• Determine the current practice at our institution and identify area of potential improvement 
• To develop a referral pathway to a complex contraception clinic as a quality improvement initiative.

Conflict of Interest​

Jaime Jessen

Universal Testing of Endometrial Cancer: Reaching an Under-Served Population (UTERUS Project)

Learning objectives:

At the end of this session, participants will: 

• Assess the importance for universal MMR IHC tumour testing for all newly diagnosed endometrial cancers. 
• Recognize the proportion of IHC deficient tumors that are due to Lynch Syndrome. 
• Apply molecular testing follow up in your practice to appropriate patients.  

Conflict of Interest

Johan Smith

The association between body mass index and the molecular types of endometrial cancer.

Learning objectives:

At the end of this session, participants will: 

• Understand the rising prevalence of endometrial cancer and its association with obesity, particularly in high-income countries.
• Recognize the strong correlation between body mass index (BMI) and endometrial cancer, with a relative risk increase of 1.59 per 5 kg/m2 increase in BMI.
• Gain knowledge about the limitations of the traditional Bokhmann classification and the inconsistent risk stratification within this model.
• Familiarize with the four molecular subsets of endometrial cancer described by The Cancer Genome Atlas (TCGA) and the more clinically practical PROMISE algorithm.
• Explore the role of obesity in tumor development, growth, and prognosis within the molecular classification system of endometrial cancer.
• Understand the prevalence of different molecular subtypes and histotypes in a real-world setting.
• Analyze the mean BMI across different molecular subtypes and histotypes and identify significant differences between groups.
• Comprehend the importance of studying the correlation between BMI and molecular subsets to improve risk assessment and treatment strategies for endometrial cancer.
• Understand the implications of the NSMP molecular subtype and its resemblance to Type 1 endometrial cancer.
• Recognize the high prevalence of NSMP cases and the potential implications of its molecularly silent or indolent nature.
• Appreciate the potential of targeted molecular therapies within each molecular subgroup of endometrial cancer.
• Understand the importance of POLE testing in risk classification and treatment decision-making.
• Gain insights into the heterogeneous nature of endometrial cancer and the significance of molecular subtyping for treatment and prognosis.

Conflict of Interest​

Kara Terry

Update guidelines are required for routine thromboprophylaxis after minimally invasive surgery in gynecologic oncology.

Learning objectives:

At the end of this session, participants will: 

• Understand the lack of evidence-based guidelines on thromboprophylaxis in minimally invasive surgery in gyne oncology
• Appreciate the low numbers of VTE after MIS in gyne onc
• Identify risk factors that may contribute to the development of VTE after MIS in gyne onc

Conflict of Interest​

Lauren Adolph

Follow-Up Of Women with Cervical Adenocarcinoma In Situ Treated by Conization: a single centre clinical experience.

Learning objectives:

At the end of this session, participants will: 

• Describe how cervical AIS is treated with a fertility sparing approach
• Identify risk factors for recurrence of cervical AIS when it is treated conservatively
• Determine if a conservative/fertility sparing approach to cervical AIS treatment is ontologically safe

Conflict of Interest

Mallika Makkar

Post-operative cognitive decline in patients undergoing gynecologic oncology surgery: a preliminary prospective study.

Learning objectives:

At the end of this session, participants will: 

• Consider the potential impact of post-operative cognitive decline on patient quality of life
• Learn a convenient patient-centred approach to mixed-methods clinical research assessment
• Identify options for subjective and objective approaches to assessing cognitive function among surgical patients

Conflict of Interest​

Melissa Lavecchia

Education modalities for serious illness communication training: A scoping review on the impact on clinician behavior and patient outcomes.

Learning objectives:

At the end of this session, participants will: 

• Identify education modalities commonly used in serious illness communication training.
• Recognize the limitations of previous studies in measuring clinician behavior change and patient outcomes.
• Discuss the need for well-defined education modalities and consistent outcome measures to enhance the evidence for serious illness communication training.

Mental health among women with a history of gynecologic cancers: A cross-sectional analysis of the Canadian Longitudinal Study on Aging.

Learning objectives:

At the end of this session, participants will: 

• Describe the mental health outcomes of gynecologic cancer survivors based on the findings of the study.
• Identify factors contributing to current mental health outcomes among gynecologic cancer survivors, including predictors of poor self-rated mental health, psychological distress, and depression.

Air travel and thromboembolism among postoperative gynecologic cancer patients: Ten-year single-centre experience prior to the era of postoperative extended thromboprophylaxis.

Learning objectives:

At the end of this session, participants will: 

• Describe the association between air travel and major abdominal surgery with an increased risk of venous thromboembolism (VTE).
• Evaluate the impact of extended duration anticoagulation on the occurrence of postoperative VTE in the studied population.
• Assess the relevance of the study findings to the Canadian health care context.

Conflict of Interest​

Sabrina Piedimonte

Evaluating the real-word impact of first line PARP-inhibitor maintenance therapy in patients with BRCA mutated Ovarian cancer

Learning objectives:

At the end of this session, participants will: 

• Recognize the real world use of olaparib in the clinical setting 
• Assess the benefit in progression free survival in BRCA patients compared to those not receiving olaparib
• Discuss the toxicity of olaparib in the real world first line setting 

Conflict of Interest​

Sarah Mah

Impact of timing of palliative care initiation on aggressiveness of end-of-life care and health resource utilization.

Learning objectives:

At the end of this session, participants will: 

• To understand evidence-based metrics of aggressive and supportive end-of-life care. 
• To identify trends in the timing of palliative care initiation in gynecologic cancer decedents in Ontario, Canada.
• To examine the impact of the timing of palliative care initiation on the aggressiveness of end-of-life care in gynecologic oncology.
• To develop strategies to improve access to early palliative care to optimize end-of-life health care quality and health resource use.

Conflict of Interest​

Sean Zhu

Recurrent Endometrial Cancer Post Robotic Hysterectomy



Learning objectives:

At the end of this session, participants will: 

• To review and identify rates and patterns of endometrial cancer recurrence post robotic 

Conflict of Interest​

Soukaina Hguig

The use of the Alexis wound retractor for extraction of large pelvic masses during robotic surgery in gyn-oncology.

Learning objectives:

At the end of this session, participants will: 

• Determine the efficacy of the Alexis wound retractor for extraction of large pelvic masses during robotic surgery in gyn-oncology.
• Establish an overview of perioperative and postoperative factors associated with pelvic mass extraction with the Alexis wound retractor. 

Conflict of Interest​

Tahereh Zadabedini Masouleh

The uptake of opportunistic salpingectomy as a benign gynecologic surgery in the general population of Newfoundland and Labrador.

Learning objectives:

At the end of this session, participants will:

• Identify the latest trend in use of opportunistic salpingectomy in Canada
• Describe the uptake of opportunistic salpingectomy in general population of Newfoundland and Labrador 

Conflict of Interest​

Tina Gao



Is there a role for intraperitoneal chemotherapy in early stage pelvic high-grade serous carcinoma? 

Learning objectives:

At the end of this session, participants will: 

• Compare progression-free survival, time to recurrence and overall survival between IP/IV chemotherapy and IV chemotherapy alone for early stage HGSC
• Identify the effect of BRCA status on the outcomes between the two treatment cohorts 
• Evaluate if IP/IV chemotherapy is a reasonable and feasible option for patients with early stage HGSC  

Conflict of Interest​

Yasmine Ayari

Effectiveness of a thromboprophylaxis protocol in a high volume gynaecological oncological Canadian center.

Learning objectives:

At the end of this session, participants will: 

• Describe the occurrence of thromboembolic events in women undergoing gynaecological oncological surgeries in a single high volume center.
• Determine the efficacy of a single high volume gynaecological oncological surgical center's thromboprophylaxis protocol.

Conflict of Interest​

Xing Zeng

Open-Label, Phase 2, Randomized Controlled Multicenter Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Patients with Homologous Recombination–Deficient Stage III/IV Ovarian Cancer: Trial in Progress.

Learning objectives:

At the end of this session, participants will: 

Will have a comprehensive understanding of the primary objective of the OPAL-C study, which aims to evaluate the efficacy, safety, and tolerability of niraparib in the neoadjuvant setting in comparison with neoadjuvant platinum-taxane doublet chemotherapy in patients with ovarian cancer with homologous recombination-deficient tumors. Participants will also gain valuable insights into the clinical trial design and methodology of the study, which will enable them to better understand the significance and potential impact of the findings.

Conflict of Interest​

Yoav Brezinov

Computer vision and robotic surgery.

Learning objectives:

At the end of this session, participants will:

• Understand the concepts of computer vision and their applications in surgical practice
• Acknowledge the advantages and challenges of robotic surgery for gynecologic cancer
• Learn about an artificial intelligence model for robotic surgery enhancement 

Conflict of Interest​

Tomer Feigenberg

Chair

Gynecologic Oncologist

Trillium Health Partners

Conflict of Interest​​​​

Sophia Pin

Chair-Elect

Gynecologic Oncologist

Cross Cancer institute

Conflict of Interest​​

Helen MacKay

Member

Medical Oncologist

Odette Cancer Centre, Sunnybrook Health 

Conflict of Interest​​​

Alon Altman

Member

Gynecologic Oncologist

CancerCare Manitoba

Conflict of Interest​​

Susie Lau

Chair

Gynecologic Oncologist

McGill University/Sir Mortimer B. Davis Jewish General Hospital

Conflict of Interest​​​

Genevieve Bouchard-Fortier

Member

Gynecologic Oncologist

Princess Margaret Cancer Centre

Conflict of Interest​​​

Rachelle Findley

Member

Gynecologic Oncologist

Nova Scotia Cancer Centre

Conflict of Interest​​​

Laurence Bernard

Member

Fellow, Postdoctoral

MD Anderson Cancer Centre

Conflict of Interest​​

Kimberly Stewart

Member

Fellow

University of British Columbia

Conflict of Interest​

George Gray

Member

Gynecologic Oncologist

Kingston health science center

Conflict of Interest​